Program
stem bromelain
Also written as “EscharEx (EX-03)”, “EX-03” and “EscharEx (5% EX-02 formulation)”.
Its studies are mostly in Varicose Ulcer · Leg Ulcer · Carcinoma, Basal Cell, led by MediWound.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| MediWound | 73 open or running | phase 3since Aug 4, 2024 | Dec 19, 2013 | Dec 2026phase 3 · NCT06568627 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 19, 2013First study: phase 2 study in Hard to Heal WoundsFirst studyNCT02020746 · 111 enrolled · Israel
- Jun 20, 2018Phase 2 study in Varicose UlcerNCT03588130 · 120 enrolled · United States, Switzerland
- Mar 16, 2021Phase 2 study in Varicose UlcerNCT04817228 · 12 enrolled · United States
- May 6, 2021Phase 2 study in Superficial Basal Cell CarcinomaNCT05157763 · 32 enrolled · United States
- Aug 4, 2024Phase 3 study in Varicose UlcerNCT06568627 · 216 planned · United States, Austria, Canada and more
- Oct 29, 2024Phase 2 study in Venus Leg UlcersNCT06690177 · 45 planned · United States, Poland
- May 4, 2026Phase 2 study in Varicose UlcerNCT07692178 · 20 planned
Ahead
- Dec 2026Primary completion: phase 3 study in Varicose UlcerNCT06568627
- Aug 2028Primary completion: phase 2 study in Varicose UlcerNCT07692178
- Nov 4, 2028Primary completion: phase 2 study in Venus Leg UlcersNCT06690177
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 7 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07692178Varicose Ulcer | 2 | Not yet recruiting | Aug 2028 | 20 |
| NCT06690177Venus Leg Ulcers · United States, Poland | 2 | Not yet recruiting | Nov 4, 2028 | 45 |
| NCT06568627Varicose Ulcer · United States, Austria, Canada and more | 3 | Recruiting | Dec 2026 | 216 |
| NCT05157763Superficial Basal Cell Carcinoma · United States | 2 | UNKNOWN | May 2022 | 32 |
| NCT04817228Varicose Ulcer · United States | 2 | Completed | May 6, 2022 | 12 |
| NCT03588130Varicose Ulcer · United States, Switzerland | 2 | Completed | Dec 7, 2021 | 120 |
| NCT02020746Hard to Heal Wounds · Israel | 2 | Completed | Dec 5, 2017 | 111 |
How it is read
Names in the registry
- “EscharEx (EX-03)”, 2 entries
- “EX-03”, 1 entry
- “EscharEx (5% EX-02 formulation)”, 1 entry
- “EscharEx (EX-02 formulation)”, 1 entry
- “EscharEx 5% (EX-02 formulation)”, 1 entry
Codes read as this program: EX03.
Conditions, from the studies’ own filings
- Varicose Ulcer, 4 studies
- Leg Ulcer, 2 studies
- Carcinoma, Basal Cell, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.